RVL Pharmaceuticals plc
DelistedCIK 1739426fmd_19GJP60W1V0F9DQT6Z14JQZXZMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2023, 24 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Total revenues | 246 | 264 | 1 | – | 18 | 50 |
| Cost of revenue | 128 | 140 | 3 | 3 | 4 | 9 |
| Gross profit | 118 | 124 | (2) | 24 | 14 | 40 |
| Research and development | 40 | 44 | 23 | 13 | 7 | 4 |
| Selling, general and administrative | 57 | 74 | 85 | 73 | 87 | 82 |
| Total operating expenses | 170 | 222 | 126 | 115 | 102 | 99 |
| Operating income | (52) | (99) | (128) | (91) | (83) | (59) |
| Interest expense | 29 | 21 | 6 | 4 | 3 | 3 |
| Other non-operating income (expense) | (5) | 1 | 1 | (0) | (1) | 6 |
| Income before taxes | (86) | (119) | (133) | (95) | (83) | (52) |
| Income tax expense | (44) | (9) | (26) | 6 | (0) | 0 |
| Net income from continuing operations | (41) | (110) | (107) | (89) | (83) | (52) |
| Net income | (41) | (110) | (271) | (80) | (65) | (52) |